300086 康芝药业
已收盘 02-10 15:00:00
资讯
新帖
简况
康芝药业：1.1亿元作为往来记入其他应付款
证券之星 · 20:51
康芝药业：1.1亿元作为往来记入其他应付款
康芝药业：目前宏氏投资已给公司支付1.1亿元履约准备金
证券日报 · 02-08 22:03
康芝药业：目前宏氏投资已给公司支付1.1亿元履约准备金
股市必读：康芝药业（300086）预计2025年全年扣非后净利润亏损1.53亿元至2.16亿元
证券之星 · 02-02
股市必读：康芝药业（300086）预计2025年全年扣非后净利润亏损1.53亿元至2.16亿元
康芝药业：预计2025年全年归属净利润亏损1.68亿元至2.38亿元
证券之星 · 01-30
康芝药业：预计2025年全年归属净利润亏损1.68亿元至2.38亿元
康芝药业盐酸左西替利嗪颗粒中选京津冀赣药品集采
中金财经 · 01-26
康芝药业盐酸左西替利嗪颗粒中选京津冀赣药品集采
康芝药业：截止目前，公司没有与脑机接口类公司合作的项目
证券之星 · 01-23
康芝药业：截止目前，公司没有与脑机接口类公司合作的项目
康芝药业（300086）披露控股股东部分股份质押展期，1月21日股价下跌0.96%
证券之星 · 01-21
康芝药业（300086）披露控股股东部分股份质押展期，1月21日股价下跌0.96%
康芝药业（300086）披露聘任高级管理人员公告，1月15日股价下跌5.04%
证券之星 · 01-15
康芝药业（300086）披露聘任高级管理人员公告，1月15日股价下跌5.04%
康芝药业：大股东已支付1.1亿元履约准备金
证券之星 · 01-12
康芝药业：大股东已支付1.1亿元履约准备金
康芝药业：控股股东已收到股权转让款
证券之星 · 2025-12-26
康芝药业：控股股东已收到股权转让款
康芝药业：目前没有海外药企投资入股情况
证券之星 · 2025-12-24
康芝药业：目前没有海外药企投资入股情况
海南封关带火旅游消费：三亚免税销售连续4天破亿 备婚情侣“打飞滴”买金 “有望成为全球度假胜地”
澎湃新闻 · 2025-12-23
海南封关带火旅游消费：三亚免税销售连续4天破亿 备婚情侣“打飞滴”买金 “有望成为全球度假胜地”
异动快报：康芝药业（300086）12月22日9点56分触及涨停板
证券之星 · 2025-12-22
异动快报：康芝药业（300086）12月22日9点56分触及涨停板
康芝药业：目前尚没有进入该试点审评审批程序的品种
证券之星 · 2025-12-19
康芝药业：目前尚没有进入该试点审评审批程序的品种
康芝药业：药品及其他产品目前主要以国内销售为主
证券之星 · 2025-12-11
康芝药业：药品及其他产品目前主要以国内销售为主
康芝药业：宏氏投资已支付1.1亿元履约准备金
证券之星 · 2025-12-11
康芝药业：宏氏投资已支付1.1亿元履约准备金
康芝药业完成董事会换届，多项治理制度修订获股东大会通过
中金财经 · 2025-12-09
康芝药业完成董事会换届，多项治理制度修订获股东大会通过
康芝药业：目前与博鳌先行区没有合作关系
证券之星 · 2025-12-03
康芝药业：目前与博鳌先行区没有合作关系
康芝药业：目前公司没有辅助生殖业务
证券之星 · 2025-11-27
康芝药业：目前公司没有辅助生殖业务
11月26日康芝药业（300086）龙虎榜数据：机构净买入3326.63万元
证券之星 · 2025-11-26
11月26日康芝药业（300086）龙虎榜数据：机构净买入3326.63万元
加载更多
公司概况
公司名称：
康芝药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-05-26
主营业务：
康芝药业股份有限公司的主营业务是儿童用药、母婴健康用品的研发、生产和销售。公司的主要产品是儿童药、母婴健康用品。爱护曾获得“广东省省级企业技术中心”、“广东省名牌产品”、“行业优秀企业”、“2024CBE美妆好品牌”等荣誉，为母婴人群提供经权威认证的、安全可靠的、健康的产品及专业服务。
发行价格：
60.00
{"stockData":{"symbol":"300086","market":"SZ","secType":"STK","nameCN":"康芝药业","latestPrice":9.38,"timestamp":1770706995000,"preClose":9.59,"halted":0,"volume":23375300,"delay":0,"changeRate":-0.0219,"floatShares":441000000,"shares":455000000,"eps":-0.4177,"marketStatus":"已收盘","change":-0.21,"latestTime":"02-10 15:00:00","open":9.53,"high":9.55,"low":9.3,"amount":220000000,"amplitude":0.0261,"askPrice":9.39,"askSize":968,"bidPrice":9.38,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-0.4177,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770773400000},"marketStatusCode":5,"adr":0,"adjPreClose":9.59,"symbolType":"stock","openAndCloseTimeList":[[1770687000000,1770694200000],[1770699600000,1770706800000]],"highLimit":10.55,"lowLimit":8.63,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":455124411,"isCdr":false,"pbRate":4.16,"roa":"--","roe":"--","epsLYR":-0.4737,"committee":0.531876,"marketValue":4269000000,"turnoverRate":0.053,"status":1,"floatMarketCap":4134000000},"requestUrl":"/m/hq/s/300086","defaultTab":"news","newsList":[{"id":"2610640138","title":"康芝药业：1.1亿元作为往来记入其他应付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610640138?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:51","pubTimestamp":1770727867,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)02月09日在投资者关系平台上答复投资者关心的问题。投资者提问：宏氏投资已给公司支付1.1亿元履约准备金，有没有加在年度报年度利润里面，还是没加进去亏损这么多，请回答康芝药业回复：尊敬投资者，您好！截至目前，宏氏投资已给公司支付1.1亿元履约准备金，1.1亿元作为往来记入其他应付款。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000036740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0070","BK0048","300086"],"gpt_icon":0},{"id":"2609574396","title":"康芝药业：目前宏氏投资已给公司支付1.1亿元履约准备金","url":"https://stock-news.laohu8.com/highlight/detail?id=2609574396","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609574396?lang=zh_cn&edition=full","pubTime":"2026-02-08 22:03","pubTimestamp":1770559380,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月30日，康芝药业在互动平台回答投资者提问时表示，关于大股东回购中山爱护股权事宜，公司始终高度重视，并在积极督促推进。目前，宏氏投资已给公司支付1.1亿元履约准备金，后续公司将继续督促大股东切实履行相关承诺，维护上市公司及全体股东的合法权益，并将严格按监管要求，及时按要求披露相关进展。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-08/doc-inhmcmei7104210.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-08/doc-inhmcmei7104210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0042","300086","BK0048","BK0070","BK0239"],"gpt_icon":0},{"id":"2608886122","title":"股市必读：康芝药业（300086）预计2025年全年扣非后净利润亏损1.53亿元至2.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608886122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608886122?lang=zh_cn&edition=full","pubTime":"2026-02-02 02:26","pubTimestamp":1769970372,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，康芝药业报收于10.14元，上涨2.22%，换手率10.06%，成交量44.34万手，成交额4.61亿元。康芝药业发布业绩预告，预计2025年全年归属净利润亏损1.68亿元至2.38亿元。公司公告汇总2025年度业绩预告康芝药业发布2025年度业绩预告，预计归属于上市公司股东的净利润亏损16,800.00万元至23,800.00万元，上年同期亏损21,620.85万元。扣除非经常性损益后的净利润预计亏损15,300.00万元至21,600.00万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086"],"gpt_icon":0},{"id":"2607001095","title":"康芝药业：预计2025年全年归属净利润亏损1.68亿元至2.38亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607001095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607001095?lang=zh_cn&edition=full","pubTime":"2026-01-30 20:11","pubTimestamp":1769775066,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业发布业绩预告，预计2025年全年归属净利润亏损1.68亿元至2.38亿元。康芝药业2025年三季报显示，前三季度公司主营收入3.26亿元，同比下降10.29%；归母净利润-9661.15万元，同比上升21.28%；扣非净利润-9863.46万元，同比上升30.23%；其中2025年第三季度，公司单季度主营收入9393.36万元，同比下降34.59%；单季度归母净利润-4252.98万元，同比下降94.49%；单季度扣非净利润-4262.75万元，同比下降17.29%；负债率42.86%，财务费用1370.45万元，毛利率53.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000041567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086"],"gpt_icon":0},{"id":"2606218965","title":"康芝药业盐酸左西替利嗪颗粒中选京津冀赣药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2606218965","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606218965?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:32","pubTimestamp":1769416326,"startTime":"0","endTime":"0","summary":"中访网数据 康芝药业股份有限公司近日发布公告，其产品盐酸左西替利嗪颗粒成功中选由河北省牵头的京津冀赣化学药品集中带量采购。根据公告，该产品中选价格为每盒36.24元。此次集采的首年约定采购量中，河北省为729,299袋，江西省为1,006,393袋。该药品主要用于治疗荨麻疹、过敏性鼻炎、湿疹等病症。 公司表示，此次中标有利于扩大该产品的市场销售规模，提升市场占有率及品牌影响力，预计将对公司的长远发展产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260126/31972498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0048","300086","BK0042","BK0239","BK0070"],"gpt_icon":0},{"id":"2605470141","title":"康芝药业：截止目前，公司没有与脑机接口类公司合作的项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2605470141","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605470141?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:51","pubTimestamp":1769172712,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)01月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司涉及人脑工程吗 或者有意向脑机接口方向发展吗康芝药业回复：您好，感谢您对公司的关注！ 截止目前，公司没有与脑机接口类公司合作的项目。敬请注意投资风险，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300040080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300086","BK0070","BK0042","BK0048"],"gpt_icon":0},{"id":"2605483852","title":"康芝药业（300086）披露控股股东部分股份质押展期，1月21日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605483852","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605483852?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:21","pubTimestamp":1769005278,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，康芝药业报收于10.34元，较前一交易日下跌0.96%，最新总市值为47.06亿元。该股当日开盘10.34元，最高10.6元，最低10.1元，成交额达2.59亿元，换手率为5.7%。近日，康芝药业发布公告称，公司控股股东海南宏氏投资有限公司将其持有的公司部分股份办理了质押展期，合计质押展期84,900,000股，占其所持股份比例83.83%，占公司总股本比例18.65%。本次质押展期不涉及新增融资，原融资用于补充经营所需资金。展期后质押到期日统一调整至2027年7月15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100040839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0070","BK0048","300086"],"gpt_icon":0},{"id":"2603985638","title":"康芝药业（300086）披露聘任高级管理人员公告，1月15日股价下跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603985638","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603985638?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:11","pubTimestamp":1768486275,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，康芝药业报收于10.54元，较前一交易日下跌5.04%，最新总市值为47.97亿元。该股当日开盘11.0元，最高11.0元，最低10.36元，成交额达5.76亿元，换手率为12.33%。公司近日发布公告称，于2026年1月15日召开第七届董事会第二次会议，审议通过《关于聘任王勇先生为公司高级管理人员的议案》，聘任王勇先生为公司副总裁。其持有公司股份30,000股，与主要股东无关联关系，未受过处罚，符合高管任职资格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500040648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","300086","BK0239","BK0042","BK0070"],"gpt_icon":0},{"id":"2602517198","title":"康芝药业：大股东已支付1.1亿元履约准备金","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517198","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602517198?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:51","pubTimestamp":1768222282,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：大股东什么时候能付清回购中山爱护的回购款？康芝药业回复：尊敬的投资者：您好！感谢您对公司的关注！关于大股东回购中山爱护股权事宜，公司始终高度重视，并在积极督促推进。目前，宏氏投资已给公司支付1.1亿元履约准备金，后续公司将继续督促大股东切实履行相关承诺，维护上市公司及全体股东的合法权益，并将严格按监管要求，及时按要求披露相关进展。敬请谨慎决策，注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200034582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0048","BK0042","300086"],"gpt_icon":0},{"id":"2594811299","title":"康芝药业：控股股东已收到股权转让款","url":"https://stock-news.laohu8.com/highlight/detail?id=2594811299","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594811299?lang=zh_cn&edition=full","pubTime":"2025-12-26 20:52","pubTimestamp":1766753550,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业12月26日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：公司大股东转让给北京晨乐私募已经2025年10月完成股权交割登记，请问大股东收到该款了吗？公司控股股东宏氏投资已收到股权转让款。目前，宏氏投资已给公司支付1.1亿元履约准备金，后续公司将严格按监管要求，及时按要求披露相关进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600033323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0048","300086","BK0042","BK0070"],"gpt_icon":0},{"id":"2593340472","title":"康芝药业：目前没有海外药企投资入股情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2593340472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593340472?lang=zh_cn&edition=full","pubTime":"2025-12-24 20:52","pubTimestamp":1766580770,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：有海外药企相关投资入股的情况吗？康芝药业回复：尊敬的投资者，您好！目前公司没有收到您所述信息，不属实，谢谢！公司的重大事项，恳请均以官方发布信息为准。若有重大合作或资本运作计划，公司将按相关法律法规要求及时履行信息披露义务。敬请注意投资风险，理性决策。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400037496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086","BK0070","BK0048","BK0239","BK0042"],"gpt_icon":0},{"id":"2593592554","title":"海南封关带火旅游消费：三亚免税销售连续4天破亿 备婚情侣“打飞滴”买金 “有望成为全球度假胜地”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593592554","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593592554?lang=zh_cn&edition=full","pubTime":"2025-12-23 08:07","pubTimestamp":1766448448,"startTime":"0","endTime":"0","summary":"【海南封关带火旅游消费：三亚免税销售连续4天破亿 备婚情侣“打飞滴”买金 “有望成为全球度假胜地”】据12月18日海南自贸港正式启动全岛封关运作以来，三亚市商务局已经连续4天发布“喜报”，12月18日至21日，三亚全市的免税销售额分别为1.18亿元、1.05亿元、1.08亿元和1.02亿元，连续4天破亿。其中，12月19日三亚全市全年累计销售额突破200亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233598872256.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233598872256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600221","LU0326950275.SGD","BK0201","BK0210","LU1146622755.USD","BK0196","BK0010","000886","BK0012","300086","BK0092","BK0188","LU1328615791.USD","BK0273","LU2328871848.SGD","BK0086","601888","BK0040","BK0042","BK0227","BK0280","BK0048","BK0239","IE0005HP3H50.USD","000796","BK0132","300189","BK0187","LU1820825898.SGD","BK0022","LU1064131003.USD","LU0593848301.USD","600515","BK0175","BK0077","LU1969619763.USD","LU2148510915.USD","BK0104","LU1997245094.SGD","BK0028","LU1064130708.USD","LU1997245177.USD","BK0101","BK0085","BK0070","BK0183"],"gpt_icon":0},{"id":"2593720211","title":"异动快报：康芝药业（300086）12月22日9点56分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2593720211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593720211?lang=zh_cn&edition=full","pubTime":"2025-12-22 10:01","pubTimestamp":1766368913,"startTime":"0","endTime":"0","summary":"证券之星12月22日盘中消息，9点56分康芝药业触及涨停板。其所属行业化学制药目前上涨。该股为海南概念，海南自由贸易港，自由贸易港概念热股，当日海南概念概念上涨8.26%，海南自由贸易港概念上涨7.93%，自由贸易港概念上涨3.73%。12月19日的资金流向数据方面，主力资金净流入2818.73万元，占总成交额2.77%，游资资金净流入309.29万元，占总成交额0.3%，散户资金净流出3128.02万元，占总成交额3.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200003394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0048","BK0042","300086"],"gpt_icon":0},{"id":"2592642101","title":"康芝药业：目前尚没有进入该试点审评审批程序的品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2592642101","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592642101?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148763,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业12月19日在投资者关系平台上答复投资者关心的问题。经核实，公司目前尚没有进入该试点审评审批程序的品种。公司始终密切关注国家及地方在医药监管领域的政策动态与改革方向，包括海南省此次开展的试点工作。未来，如公司有符合试点条件的业务开展计划，将根据相关法规及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900036506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","BK0239","BK0042","BK0070","300086"],"gpt_icon":0},{"id":"2590451518","title":"康芝药业：药品及其他产品目前主要以国内销售为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590451518?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:48","pubTimestamp":1765457302,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问贵公司有海外市场吗？如果有，具体是哪些业务，哪些国家呢？日本现在流感很严重，贵公司的产品有向日本销售吗？康芝药业回复：您好，公司的药品及其他产品目前主要以国内销售为主，几乎无外销。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100038181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0042","300086","BK0048","BK0239"],"gpt_icon":0},{"id":"2590960515","title":"康芝药业：宏氏投资已支付1.1亿元履约准备金","url":"https://stock-news.laohu8.com/highlight/detail?id=2590960515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590960515?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:48","pubTimestamp":1765457301,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司股东回购子公司事项进展如何？康芝药业回复：尊敬的投资者，您好！关于宏氏投资的回购方案，公司始终在积极督促推进。目前，宏氏投资已给公司支付1.1亿元履约准备金，后续公司将严格按监管要求，及时按要求披露相关进展。公司通过深交所互动易、投资者热线及创业板指定的信息披露网站披露公司相关信息，敬请谨慎决策，注意投资风险。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100038180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0048","300086","BK0070"],"gpt_icon":0},{"id":"2590497363","title":"康芝药业完成董事会换届，多项治理制度修订获股东大会通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2590497363","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590497363?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:17","pubTimestamp":1765286224,"startTime":"0","endTime":"0","summary":"中访网数据 康芝药业股份有限公司于2025年12月9日成功召开了2025年第一次临时股东大会。会议审议并通过了公司董事会换届选举及多项治理制度的修订议案。本次会议共有379名股东参与表决，代表股份占公司有表决权股份总数的27.0021%，其中通过网络投票的中小股东371人。新一届董事会的组建及公司治理制度的全面修订与完善，标志着康芝药业在公司治理结构上迈出了重要一步，旨在进一步提升公司规范运作水平和决策效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251209/31854442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK0070","BK0042","BK0048","300086"],"gpt_icon":0},{"id":"2588469380","title":"康芝药业：目前与博鳌先行区没有合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2588469380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588469380?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:49","pubTimestamp":1764766175,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：“作为乐城先行区首批特许药械代理机构，公司与博鳌先行区是否有合作关系？康芝药业回复：尊敬的投资者，您好！感谢您对公司的关注。目前公司尚未取得海南博鳌乐城国际医疗旅游先行区等相关区域的特许药械代理资质，且目前公司与博鳌先行区没有合作关系。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300086","BK0048","BK0070","BK0239"],"gpt_icon":0},{"id":"2586024043","title":"康芝药业：目前公司没有辅助生殖业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2586024043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586024043?lang=zh_cn&edition=full","pubTime":"2025-11-27 20:48","pubTimestamp":1764247736,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问公司是否有辅助生殖业务?康芝药业回复：尊敬的投资者您好，感谢您对公司的关注！目前公司没有辅助生殖业务！谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700035404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0070","300086","BK0048","BK0239"],"gpt_icon":0},{"id":"2586258864","title":"11月26日康芝药业（300086）龙虎榜数据：机构净买入3326.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586258864","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586258864?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:49","pubTimestamp":1764150584,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年11月26日公布的交易公开信息显示，康芝药业因日换手率达到30%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年11月26日收盘，康芝药业报收于12.97元，上涨5.62%，换手率37.56%，成交量165.53万手，成交额21.99亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入3326.63万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600027077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300086","BK0048","BK0239","BK0042"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770736551732,"stockEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":-0.1683},{"period":"3month","weight":0.1048},{"period":"6month","weight":0.3155},{"period":"1year","weight":0.9855},{"period":"ytd","weight":-0.2028}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康芝药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41838人(较上一季度增加31.29%)","perCapita":"10533股","listingDate":"2010-05-26","address":"海南省海口市秀英区国家高新技术产业开发区药谷工业园药谷三路6号","registeredCapital":"45512万元","survey":" 康芝药业股份有限公司的主营业务是儿童用药、母婴健康用品的研发、生产和销售。公司的主要产品是儿童药、母婴健康用品。爱护曾获得“广东省省级企业技术中心”、“广东省名牌产品”、“行业优秀企业”、“2024CBE美妆好品牌”等荣誉，为母婴人群提供经权威认证的、安全可靠的、健康的产品及专业服务。","listedPrice":60},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康芝药业(300086)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康芝药业(300086)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康芝药业,300086,康芝药业股票,康芝药业股票老虎,康芝药业股票老虎国际,康芝药业行情,康芝药业股票行情,康芝药业股价,康芝药业股市,康芝药业股票价格,康芝药业股票交易,康芝药业股票购买,康芝药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康芝药业(300086)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康芝药业(300086)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}